Neuralstem has entered into a sponsored research agreement with the China Medical University & Hospital of Taiwan, to prepare for a human clinical trial (using Neuralstem’s human spinal cord neural stem cells) to treat stroke patients.
The company said that the therapy will focus on patients whose post-stroke symptoms, including complete or partial paralysis, have stopped improving more than six months after an ischemic stroke.
Richard Garr, President and CEO of Neuralstem, said: “We are excited to be moving forward in treating stroke with our cells. The preclinical program, which we expect will take between nine months to a year, will focus on qualifying our existing cGMP (Good Manufacturing Process) spinal cord cells into a human trial program to treat post-stroke symptoms in Taiwan.”